Point of Care & Rapid Diagnostics市場：製品（グルコース、感染症（HIV、C型肝炎）、妊娠検査）、プラットフォーム（マイクロ流体、点滴）、購入形態（OTC、処方）、エンドユーザー（薬局、病院、家庭）別 - 2027年までの世界市場予測

Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) - Global Forecast to 2027

世界のPOC診断市場は、2022年の推定432億米ドルから2027年には720億米ドルに達し、2022年から2027年までのCAGRは10.8％と予測されています。ポイントオブケア検査（POCT）には、従来の検査室以外で実施されるスク... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年3月8日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	359	317	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のPOC診断市場は、2022年の推定432億米ドルから2027年には720億米ドルに達し、2022年から2027年までのCAGRは10.8％と予測されています。ポイントオブケア検査（POCT）には、従来の検査室以外で実施されるスクリーニング検査や診断検査が含まれます。これらの検査は、患者がいる場所またはその近辺（自宅、救急車内、医院など）で使用されるように設計されています。POCTは、迅速かつ信頼性の高い診断検査を可能にし、その結果を即座に得ることができるため、医師や患者が遠隔で、できるだけ早く治療に関する意思決定を行えるよう支援します。市場成長の主な要因は、感染症の流行、政府の支援政策、CLIA認証取得済みPOC検査数の増加です。また、医療の分散化、製品開発への投資や資金調達の拡大が、POC診断市場のプレーヤーに成長機会を提供すると期待されています。POC検査は、特にタイムリーな医療へのアクセスが難しく、医療インフラが古くまばらな発展途上国において、感染症管理を大幅に改善することができます。UNAIDSによると、2018年、東・南アフリカのHIV感染者は約2,060万人でした。2019年には、中東・北アフリカで2万人の新規HIV感染者が登録されました（出典：UNAIDS Data 2020）。アジア太平洋地域では、2019年にインドと中国が主導して、推定580万人がHIVに感染していました。UNAIDSによると、2019年、インドでは約210万人がHIVに感染しています。HIVの高い感染率は、ポイントオブケア診断薬の需要を押し上げ、HIV感染症の治療をさらに加速させると思われます。

以下に、発展途上国における主要な感染症に関連する重要な統計データを掲載します。
WHOによると、インドは結核の負担が最も大きく、2020年には264万人の患者が発生すると推定されています。
- 2019年には、東南アジアで約430万人の新規結核患者が報告され、この地域で結核感染症が原因で63万2000人が死亡しています（出典：WHO）。
- 国家インフルエンザ政策2017によると、南アフリカでは毎年約1万人の死亡と4万人の入院がインフルエンザが原因で起こっています。
- WHOによると、東南アジアでは120万人がマラリアに苦しんでおり、インドだけで全マラリア患者の〜76%を占めています。
- 2014年から2016年にかけて、西アフリカでは地域最大のエボラ出血熱の流行が報告され、2年半の間に28,600人以上の患者と11,325人の死者を出した。
- 2020年、ブラジルでは推定15,898人がジカウイルス感染症のリスクにさらされ、前年に報告された30,000人以上の症例から減少しました。

発展途上国では、感染症が高い頻度で発生し、医療インフラ設備も不十分であることから、POC検査の普及が進むと予想されます。

"2021年のPoint of Care診断薬市場において、製品タイプ別ではグルコースモニタリング製品分野が最大のシェアを占めています"

ポイントオブケア診断薬市場は、製品別に、グルコースモニタリング製品、循環代謝モニタリング製品、COVID-19検査製品、感染症検査製品、凝固モニタリング製品、妊娠・不妊検査製品、血液検査製品、腫瘍・がんマーカー検査製品、便潜血検査製品、尿検査製品、乱用薬検査製品、コレステロール検査製品、その他に分類されます。2021年のポイントオブケア診断薬市場では、グルコースモニタリング製品部門が最大のシェアを占めています。これは、糖尿病患者数の増加、継続的な技術の進歩、在宅グルコース検査への嗜好の高まりに起因していると考えられます。

"2021年のPoint of Care診断薬市場（プラットフォーム別）では、ラテラルフローアッセイ部門が最大のシェアを占めました。"

ポイントオブケア診断薬市場は、プラットフォームに基づいて、ラテラルフローアッセイ、イムノアッセイ、マイクロフルイディクス、ディップスティック、分子診断薬に区分されます。2021年の市場では、ラテラルフローアッセイセグメントが最大のシェアを占めています。時間がかかる従来のラボ手順の代替として、POC検査でラテラルフローアッセイが広く採用されていることが、このセグメントの成長に寄与している主な要因です。

"2021年のPoint of Care Diagnostics世界市場において、購入形態別のOTC検査製品セグメントが最大のシェアを占めました。"

購入形態に基づき、ポイントオブケア診断薬市場はOTC検査製品と処方箋に基づく検査製品に区分されます。2021年の市場では、OTC検査製品部門が最大のシェアを占めています。生活習慣病の蔓延の増加や、OTC検査製品に対する有利な償還シナリオが、この市場セグメントの成長を促進する主な要因となっています。

"エンドユーザー別では、病院・重症患者センター部門が、2021年の世界のPOC診断市場で最大のシェアを占めています"

エンドユーザー別に見ると、ポイントオブケア診断薬市場は、臨床検査室、外来診療施設・医院、薬局・小売クリニック・Eコマースプラットフォーム、病院・救命救急センター・緊急医療センター、在宅医療・自己診断、その他のエンドユーザーに区分されます。病院・救命救急センター分野は、所要時間の短縮を実現するPOCデバイスの採用が進んでいることから、予測期間中に市場を支配するものと思われます。2021年のポイントオブケア診断薬市場では、臨床検査室部門が最大のシェアを占めています。しかし、慢性疾患（長期的なケアと頻繁なモニタリングを必要とする）の有病率の増加、在宅ケアに関する意識の高まり、ユーザーフレンドリーで高度なPOC診断製品の入手の増加により、在宅ケアおよび自己診断部門が予測期間中に最も高いCAGRを記録すると予測されます。

"中南米市場は予測期間中に最も高いCAGRで成長すると予想される"

世界のPOC診断市場は、北米（米国、カナダを含む）、欧州（ドイツ、フランス、英国を含む）、アジア太平洋地域（日本、中国、インドを含む）、中南米（ブラジル、メキシコ）、中東・アフリカに区分されます。2021年には、北米が最大のシェアを占め、欧州がこれに続きました。生活習慣病の有病率の上昇、製品承認の増加、POC検査製品の幅広い採用を支援する政府の取り組みが、北米のポイントオブケア診断薬市場の成長を促す主な要因となっています。一方、中南米市場は、疾病の早期発見や定期的な健康診断に関する意識を高めるための政府の取り組みがポイントオブケア機器をさらに促進し、予測期間中に最も高い成長を記録すると予測されます。

本レポートで参照した主な参加企業の内訳は以下のとおりです。
- 企業タイプ別Tier 1-48%, Tier 2-36%, Tier 3- 16
- 役職別Cレベル-10％、ディレクターレベル-14％、その他-76
- 地域別北米-40％、欧州-32％、アジア太平洋-20％、中南米-5％、中東・アフリカ-3％。

2020年時点のPOC診断市場は、Roche Diagnostics（スイス）、Abbott Laboratories（米国）、Siemens Healthineers（ドイツ）、Danaher Corporation（米国）、Quidel Corporation（米国）が支配的である。その他の主要プレイヤーは、Becton, Dickinson, and Company（米国）、Biomeriux S.A.（フランス）、Chembio Diagnostics（米国）である。

調査対象

本レポートでは、製品タイプ、プラットフォーム、購入形態、エンドユーザー、地域に基づき、Point of Care Diagnostics市場を調査しています。また、市場成長に影響を与える要因を網羅し、市場における様々な機会や課題を分析し、市場リーダー向けの競争環境についても詳しく解説しています。さらに、ミクロ市場を個々の成長動向に関して分析し、主要5地域（およびこれらの地域のそれぞれの国）に関して市場セグメントの売上を予測しています。

レポート購入の理由
本レポートは、既存企業だけでなく、新規参入企業や中小企業も市場の動向を把握することができ、ひいてはより大きな市場シェアを獲得するのに役立つものと思われます。本レポートを購入された企業は、以下の戦略の1つまたは複数を組み合わせて、市場での存在感を高めることができます。

本レポートでは、以下のポイントについて考察しています。
市場の浸透。ポイントオブケア診断薬市場のトッププレイヤーが提供する製品ポートフォリオに関する包括的な情報
製品開発/イノベーション。ポイントオブケア診断薬市場における今後の動向、研究開発活動、製品の上市に関する詳細な洞察
市場開拓。有利な新興地域に関する包括的な情報
市場の多様化。ポイントオブケア診断薬市場における新製品、成長地域、最新動向に関する徹底的な情報提供
競争力のある評価。市場セグメント、成長戦略、収益分析、主要な市場プレイヤーの製品に関する詳細な評価。

ページTOPに戻る

Table of Contents

Summary

The global point of care diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027. Point-of-care testing (POCT) includes screening or diagnostic tests performed outside traditional laboratories. These tests are designed to be used at or near the site where the patient is located (such as at home, in an ambulance, at a physician’s office, and other locations). POCT allows rapid and reliable diagnostic testing through which outcomes can be obtained instantly, helping physicians/patients to make decisions related to care remotely and as soon as possible. Market growth is mainly driven by the high prevalence of infectious diseases, supportive government policies and rising number of CLIA-waived POC tests. In addition, healthcare decentralization and greater investments and funding for product development are expected to offer growth opportunities for players in the point of care diagnostics market. POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. According to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. In 2019, 20,000 new HIV cases were registered in the Middle East and North Africa (Source: UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection.

Listed below are important statistics related to major infectious diseases in developing countries:
According to the WHO, India has the highest tuberculosis burden, with an estimated incidence of 2.64 million cases in 2020.
• In 2019, around 4.3 million new tuberculosis cases were reported in Southeast Asia, and 632,000 people died due to TB infections in this region (Source: WHO).
• According to the National Influenza Policy 2017, around 10,000 deaths and 40,000 hospitalizations are caused due to influenza in South Africa each year.
• According to the WHO, 1.2 million people in Southeast Asia suffer from malaria, with India alone accounting for ~76% of the total malaria cases.
• During 2014–2016, West Africa reported the largest Ebola epidemic in the region; in two and a half years, the outbreak resulted in more than 28,600 cases and 11,325 deaths.
• In 2020, an estimated 15,898 people in Brazil were at risk of Zika virus infections, down from over 30,000 cases reported a year earlier.

The high prevalence of infectious diseases, coupled with the inadequate healthcare infrastructural facilities in developing countries, is expected to drive the adoption of POC testing.

“The Glucose Monitoring Products segment accounted for the largest share of the point of care diagnostics market, by product type, in 2021”

Based on products, the point-of-care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, tumor/cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, cholesterol testing products, and other products. In 2021, the glucose monitoring products segment accounted for the largest share of the point-of-care diagnostics market. This can be attributed to the growing diabetic patient population base, ongoing technological advancements, and the growing preference for home glucose testing.

“The Lateral Flow Assays segment accounted for the largest share of the point of care diagnostics market, by platform, in 2021”

Based on platform, the point-of-care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2021. The widespread adoption of lateral flow assays in POC testing as a replacement for lengthy, conventional laboratory procedures is a key factor contributing to the growth of this segment.

“The OTC Testing Products segment, by mode of purchase, accounted for the largest share of the global point of care diagnostics market in 2021”

On the basis of mode of purchase, the point-of-care diagnostics market is segmented into OTC testing products and prescription-based testing products. The OTC testing products segment accounted for the largest share of the market in 2021. The growing prevalence of lifestyle diseases and the favorable reimbursement scenario for OTC testing products are the major factors driving the growth of this market segment.

“On the basis of End Users, Hospitals & Critical Care Centers segment accounted for the largest share of the global point of care diagnostics market, in 2021”

On the basis of end users, the point-of-care diagnostics market is segmented into clinical laboratories; ambulatory care facilities and physicians’ offices; pharmacies, retail clinics, and E-commerce platforms; hospitals, critical care centers, and urgent care centers; home care & self-testing; and other end users. The hospitals & critical care centers segment is expected to dominate the market during the forecast period, owing to the increasing adoption of POC devices offering reduced turnaround time. The clinical laboratories segment accounted for the largest share of the point-of-care diagnostics market in 2021. However, the home care and self-testing segment is projected to register the highest CAGR during the forecast period, owing to the increasing prevalence of chronic diseases (requiring long-term care and frequent monitoring), growing awareness about home care, and the increasing availability of user-friendly and advanced POC diagnostic products.

“The Latin America market is expected to grow at the highest CAGR during the forecast period”

The global point of care diagnostics market is segmented into North America (comprising the US and Canada), Europe (includes Germany, France, and the UK), the Asia Pacific (includes Japan, China, India), Latin America (Brazil, Mexico), and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. The rising prevalence of lifestyle diseases, growing number of product approvals, and government initiatives to support the wider adoption of POC testing products are the key factors driving the growth of the North American point-of-care diagnostics market. On the other hand, the Latin American market is projected to register the highest growth during the forecast period due to government efforts to increase awareness about the early detection of diseases and regular health check-ups, further promoting point-of-care devices.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: C-level–10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

As of 2020, the point of care diagnostics market is dominated by Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Quidel Corporation (US). Other leading players are Becton, Dickinson, and Company (US), Biomeriux S.A. (France), and Chembio Diagnostics (US).

Research Coverage

This report studies the point of care diagnostics market based on product type, platform, mode of purchase, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the point of care diagnostics market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the point of care diagnostics market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the point of care diagnostics market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

1 INTRODUCTION 39

1.1 OBJECTIVES OF THE STUDY 39

1.2 MARKET DEFINITION 39

1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 40

1.3 MARKET SCOPE 41

1.3.1 YEARS CONSIDERED FOR THE STUDY 42

1.4 CURRENCY USED FOR THE STUDY 42

TABLE 1 STANDARD CURRENCY CONVERSION RATES 42

1.5 LIMITATIONS 43

1.6 KEY MARKET STAKEHOLDERS 43

1.7 SUMMARY OF CHANGES 43

2 RESEARCH METHODOLOGY 45

2.1 RESEARCH DATA 45

FIGURE 1 RESEARCH DESIGN 45

2.1.1 SECONDARY DATA 46

2.1.1.1 Indicative list of secondary sources 47

2.1.2 PRIMARY DATA 48

2.1.2.1 Key industry insights 49

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,

DESIGNATION, AND REGION 49

FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 50

2.2 MARKET ESTIMATION METHODOLOGY 50

2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 51

2.2.2 END-USER-BASED MARKET ESTIMATION 52

FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY:

POINT-OF-CARE DIAGNOSTICS MARKET 52

FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 53

2.2.3 PRIMARY RESEARCH VALIDATION 53

2.3 COVID-19 HEALTH ASSESSMENT 54

2.4 COVID-19 ECONOMIC ASSESSMENT 54

2.5 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 55

FIGURE 6 CRITERIA IMPACTING THE GLOBAL ECONOMY 55

FIGURE 7 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 56

2.6 DATA TRIANGULATION 57

FIGURE 8 DATA TRIANGULATION METHODOLOGY 57

2.7 RESEARCH ASSUMPTIONS & LIMITATIONS 58

2.7.1 ASSUMPTIONS FOR THE STUDY 58

2.8 RESEARCH LIMITATIONS 58

3 EXECUTIVE SUMMARY 59

FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2021 VS. 2027 (USD MILLION) 59

FIGURE 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,

2021 VS. 2027 (USD MILLION) 60

FIGURE 11 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,

2021 VS. 2027 (USD MILLION) 61

FIGURE 12 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,

2021 VS. 2027 (USD MILLION) 61

FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE POINT-OF-CARE DIAGNOSTICS MARKET 62

4 PREMIUM INSIGHTS 63

4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW 63

FIGURE 14 RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH 63

4.2 IMPACT OF COVID-19 ON THE GLOBAL POINT-OF-CARE DIAGNOSTICS

MARKET (USD MILLION) 64

FIGURE 15 MARKET TO WITNESS A RISE DURING 2020–2021 OWING TO THE PANDEMIC 64

4.3 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY MODE OF PURCHASE (2021) 64

FIGURE 16 OTC TESTING PRODUCTS DOMINATED THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2021 64

4.4 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER

AND COUNTRY (2021) 65

FIGURE 17 HOME CARE & SELF-TESTING IS THE LARGEST END-USER SEGMENT OF THE APAC POC DIAGNOSTICS MARKET 65

4.5 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 66

FIGURE 18 LATIN AMERICA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2022–2027) 66

5 MARKET OVERVIEW 67

5.1 INTRODUCTION 67

5.2 MARKET DYNAMICS 67

FIGURE 19 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67

5.2.1 DRIVERS 68

5.2.1.1 High prevalence of infectious diseases 68

5.2.1.2 Increasing incidence of target conditions 68

5.2.1.3 Supportive government policies 69

5.2.1.4 Dearth of skilled laboratory technicians 69

5.2.1.5 Rising number of CLIA-waived POC tests 70

TABLE 2 RECENT WAIVERS FOR MARKET PRODUCTS 70

5.2.2 RESTRAINTS 70

5.2.2.1 Pricing pressure owing to reimbursement cuts and

budget constraints 70

5.2.2.2 Stringent regulatory policies 71

5.2.3 OPPORTUNITIES 71

5.2.3.1 Emerging markets 71

5.2.3.2 Healthcare decentralization 72

5.2.3.3 Increasing provider awareness about novel technologies 72

5.2.3.4 POC tests with multiplexing capabilities 73

5.2.3.5 Growing investments and funding for product development 73

5.2.4 CHALLENGES 74

5.2.4.1 Lack of alignment with definitive central lab methods 74

5.2.4.2 Inadequate adoption of POC devices in professional settings 74

5.2.4.3 Reluctance to change existing diagnostic practices 75

5.2.4.4 Premium pricing of novel platforms 75

5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS 75

5.3.1 SEPSIS BIOMARKERS 75

5.3.2 STROKE/CARDIAC MARKERS 76

5.3.3 THYROID TESTING 77

5.3.4 DNA TESTING 77

5.3.5 ENDOCRINE TESTING 77

5.3.6 RESPIRATORY DIAGNOSTICS 77

5.4 REGULATORY LANDSCAPE 78

5.5 INDUSTRY TRENDS RELATED TO COVID-19 79

5.6 VALUE CHAIN ANALYSIS 79

FIGURE 20 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THE REGULATION AND DISTRIBUTION STAGES 79

5.7 SUPPLY CHAIN ANALYSIS 80

5.7.1 PROMINENT COMPANIES 80

5.7.2 SMALL & MEDIUM-SIZED ENTERPRISES 80

5.7.3 END USERS 81

FIGURE 21 SUPPLY CHAIN ANALYSIS 81

5.8 PRICING TREND ANALYSIS 81

TABLE 3 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2021 (USD) 81

TABLE 4 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS,

BY COUNTRY, 2021 (USD) 82

TABLE 5 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS,

BY COUNTRY, 2021 (USD) 82

5.9 PORTER’S FIVE FORCES 83

5.9.1 OVERVIEW 83

TABLE 6 POINT-OF-CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 83

5.9.2 BARGAINING POWER OF BUYERS 83

5.9.3 BARGAINING POWER OF SUPPLIERS 83

5.9.4 THREAT OF NEW ENTRANTS 83

5.9.5 THREAT OF SUBSTITUTES 84

5.9.6 INTENSITY OF COMPETITIVE RIVALRY 84

5.10 PATENT ANALYSIS 84

FIGURE 22 PATENT APPLICANTS FOR POINT-OF-CARE TESTING 84

FIGURE 23 PATENT APPLICANTS FOR POINT-OF-CARE DIAGNOSTICS 84

FIGURE 24 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS) 85

6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 86

6.1 INTRODUCTION 87

TABLE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 87

6.2 GLUCOSE MONITORING PRODUCTS 88

TABLE 8 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 89

TABLE 10 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 89

TABLE 11 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 90

TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 90

6.2.1 STRIPS 91

6.2.1.1 Strips make blood glucose testing easy and hassle-free 91

TABLE 13 GLUCOSE MONITORING STRIPS MARKET, BY REGION,

2020–2027 (USD MILLION) 91

6.2.2 METERS 91

6.2.2.1 Blood glucose meters are extremely helpful in the monitoring of blood glucose levels and adjusting therapeutic regimens 91

TABLE 14 GLUCOSE MONITORING METERS MARKET, BY REGION,

2020–2027 (USD MILLION) 92

6.2.3 LANCETS & LANCING DEVICES 92

6.2.3.1 Lancets & lancing devices segment to register lower growth in the glucose monitoring products market 92

TABLE 15 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 92

6.3 COVID-19 TESTING PRODUCTS 93

6.3.1 ONGOING PANDEMIC HAS INCREASED THE DEMAND FOR POC DIAGNOSTIC PRODUCTS 93

TABLE 16 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 94

TABLE 17 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 94

TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 95

TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 95

6.4 CARDIOMETABOLIC MONITORING PRODUCTS 96

TABLE 20 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 96

TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE,

2020–2027 (USD MILLION) 97

TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 97

TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 98

6.4.1 CARDIAC MARKER TESTING PRODUCTS 98

6.4.1.1 Rising government initiatives for CVD research will contribute to market growth 98

TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 99

TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 99

TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 100

6.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 100

6.4.2.1 Technological advancements in blood gas/electrolyte products will drive the growth of this market segment 100

TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 101

TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 101

TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 102

6.4.3 HBA1C TESTING PRODUCTS 102

6.4.3.1 Government initiatives are promoting the regular use of

HbA1c testing 102

TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 103

TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,

BY END USER, 2020–2027 (USD MILLION) 103

TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,

BY REGION, 2020–2027 (USD MILLION) 104

6.5 INFECTIOUS DISEASE TESTING PRODUCTS 104

TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 105

TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 105

TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 106

TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 106

TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 107

6.5.1 HIV TESTING PRODUCTS 107

6.5.1.1 Rising prevalence of HIV to drive market growth 107

TABLE 39 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 108

TABLE 40 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,

BY END USER, 2020–2027 (USD MILLION) 108

TABLE 41 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,

BY REGION, 2020–2027 (USD MILLION) 109

6.5.2 RESPIRATORY INFECTION TESTING PRODUCTS 109

6.5.2.1 POCT products for the diagnosis of respiratory infections offer lower sensitivity as compared to other tests 109

TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 110

TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 110

TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 111

6.5.3 HEPATITIS C TESTING PRODUCTS 111

6.5.3.1 Central and East Asia are among the highly affected regions

with hepatitis C 111

TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 112

TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 112

TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 113

6.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 113

6.5.4.1 Rising prevalence of HAIs is the key factor driving market growth 113

TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE,

2020–2027 (USD MILLION) 113

TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 114

TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 114

6.5.5 INFLUENZA TESTING PRODUCTS 115

6.5.5.1 Rising influenza prevalence has driven the demand for influenza testing products 115

TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 115

TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 116

TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 116

6.5.6 TROPICAL DISEASE TESTING PRODUCTS 117

6.5.6.1 Increasing government funding for the use of POC in tropical disease testing will support market growth 117

TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 117

TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 118

TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 118

6.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 119

6.5.7.1 Privacy and confidentiality issues are the key factors leading to the adoption of POC STD testing products 119

TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 119

TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,

BY END USER, 2020–2027 (USD MILLION) 120

TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,

BY REGION, 2020–2027 (USD MILLION) 120

6.5.8 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 121

TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 121

TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 122

TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 122

6.6 COAGULATION MONITORING PRODUCTS 123

TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 123

TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 124

TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 124

TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 125

TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 125

6.6.1 PT/INR TESTING PRODUCTS 126

6.6.1.1 PT/INR is one of the most commonly used coagulation

monitoring methods 126

TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 126

TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,

BY END USER, 2020–2027 (USD MILLION) 127

TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,

BY REGION, 2020–2027 (USD MILLION) 127

6.6.2 ACT/APTT TESTING PRODUCTS 128

6.6.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth 128

TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 128

TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 129

TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 129

6.7 PREGNANCY & FERTILITY TESTING PRODUCTS 130

TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 130

TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 130

TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 131

TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 131

TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 132

6.7.1 PREGNANCY TESTING PRODUCTS 132

6.7.1.1 Rising inclination toward home testing to support market growth 132

TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 132

TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 133

TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 133

6.7.2 FERTILITY TESTING PRODUCTS 134

6.7.2.1 Increasing awareness of fertility testing to drive market growth 134

TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 134

TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 135

TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 135

6.8 TUMOR/CANCER MARKER TESTING PRODUCTS 136

6.8.1 INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH 136

TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 136

TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 137

TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 137

TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 138

TABLE 89 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 138

TABLE 90 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 139

6.9 DRUGS-OF-ABUSE TESTING PRODUCTS 139

6.9.1 RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED

THE DEMAND FOR TESTING 139

TABLE 91 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 140

TABLE 92 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 140

TABLE 93 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 141

TABLE 94 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 141

6.10 FECAL OCCULT TESTING PRODUCTS 142

6.10.1 LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING TO HAMPER MARKET ADOPTION 142

TABLE 95 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 142

TABLE 96 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 143

TABLE 97 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 143

TABLE 98 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 144

6.11 OTHER PRODUCTS 144

TABLE 99 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,

BY PLATFORM, 2020–2027 (USD MILLION) 144

TABLE 100 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 145

TABLE 101 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,

BY END USER, 2020–2027 (USD MILLION) 145

TABLE 102 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,

BY REGION, 2020–2027 (USD MILLION) 146

7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM 147

7.1 INTRODUCTION 148

TABLE 103 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,

2020–2027 (USD MILLION) 148

7.2 LATERAL FLOW ASSAYS 148

7.2.1 INCREASING ADOPTION OF LFA TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET GROWTH 148

TABLE 104 POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS,

BY REGION, 2020–2027 (USD MILLION) 149

7.3 IMMUNOASSAYS 149

7.3.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH 149

TABLE 105 POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION) 150

7.4 MICROFLUIDICS 150

7.4.1 MICROFLUIDICS IS AN EMERGING PLATFORM IN THE POC

DIAGNOSTICS MARKET 150

TABLE 106 POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2020–2027 (USD MILLION) 151

7.5 DIPSTICKS 151

7.5.1 DIPSTICKS HELP IN THE ROUTINE ANALYSIS OF SEVERAL

MEDICAL CONDITIONS 151

TABLE 107 POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION,

2020–2027 (USD MILLION) 152

7.6 MOLECULAR DIAGNOSTICS 152

7.6.1 INCREASING INITIATIVES BY MARKET PLAYERS FOR DEVELOPING POC MOLECULAR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH 152

TABLE 108 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY REGION, 2020–2027 (USD MILLION) 153

8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 154

8.1 INTRODUCTION 155

TABLE 109 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,

2020–2027 (USD MILLION) 155

8.2 OTC TESTING PRODUCTS 155

8.2.1 RISING FOCUS ON HOME CARE HAS BOOSTED THE DEMAND FOR

OTC TESTING PRODUCTS 155

TABLE 110 OTC POINT-OF-CARE TESTING PRODUCTS MARKET, BY REGION,

2020–2027 (USD MILLION) 156

8.3 PRESCRIPTION-BASED TESTING PRODUCTS 156

8.3.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT HAVE DRIVEN MARKET GROWTH 156

TABLE 111 PRESCRIPTION-BASED POINT-OF-CARE TESTING PRODUCTS MARKET,

BY REGION, 2020–2027 (USD MILLION) 157

9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER 158

9.1 INTRODUCTION 159

TABLE 112 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,

2020–2027 (USD MILLION) 159

9.2 CLINICAL LABORATORIES 159

9.2.1 IMPROVEMENTS IN CLINICAL DIAGNOSTICS AND TESTING TECHNOLOGIES WILL BOOST MARKET GROWTH 159

TABLE 113 POINT-OF-CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY REGION, 2020–2027 (USD MILLION) 160

9.3 AMBULATORY CARE FACILITIES & PHYSICIANS’ OFFICES 160

9.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE ARE THE MAJOR FACTORS DRIVING MARKET GROWTH 160

TABLE 114 POINT-OF-CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIANS’ OFFICES, BY REGION, 2020–2027 (USD MILLION) 161

9.4 PHARMACIES, RETAIL CLINICS, & E-COMMERCE PLATFORMS 161

9.4.1 CONVENIENCE AND EASE OF EXPERT ACCESS TO DRIVE MARKET GROWTH 161

TABLE 115 POINT-OF-CARE DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, & E-COMMERCE PLATFORMS, BY REGION, 2020–2027 (USD MILLION) 162

9.5 HOSPITALS, CRITICAL CARE CENTERS, & URGENT CARE CENTERS 162

9.5.1 HOSPITALS ARE AMONG THE LARGEST END USERS OF POC DIAGNOSTICS 162

TABLE 116 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS,

CRITICAL CARE CENTERS, & URGENT CARE CENTERS, BY REGION,

2020–2027 (USD MILLION) 163

9.6 HOME CARE & SELF-TESTING 163

9.6.1 INCREASING INCLINATION TOWARD HOME HEALTHCARE IS DRIVING THE GROWTH OF THIS END-USER SEGMENT 163

TABLE 117 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE & SELF TESTING,

BY REGION, 2020–2027 (USD MILLION) 164

9.7 OTHER END USERS 164

TABLE 118 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 165

10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 166

10.1 INTRODUCTION 167

TABLE 119 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION,

2020–2027 (USD MILLION) 167

10.2 NORTH AMERICA 168

FIGURE 25 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 168

TABLE 120 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 168

TABLE 121 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 169

TABLE 122 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 169

TABLE 123 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 170

TABLE 124 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 170

TABLE 125 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 171

TABLE 126 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 171

TABLE 127 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 171

TABLE 128 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 172

TABLE 129 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 172

10.2.1 US 173

10.2.1.1 The US dominates the North American POC diagnostics market 173

TABLE 130 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 174

TABLE 131 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 175

TABLE 132 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 175

TABLE 133 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 176

TABLE 134 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 176

10.2.2 CANADA 176

10.2.2.1 Rising government initiatives to support the growth of the

POC diagnostics market in Canada 176

TABLE 135 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 178

TABLE 136 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 178

TABLE 137 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 179

TABLE 138 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 179

TABLE 139 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 180

10.3 EUROPE 180

TABLE 140 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,

2020–2027 (USD MILLION) 180

TABLE 141 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 181

TABLE 142 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 181

TABLE 143 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 182

TABLE 144 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 182

TABLE 145 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 183

TABLE 146 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 183

TABLE 147 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,

2020–2027 (USD MILLION) 183

TABLE 148 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 184

TABLE 149 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,

2020–2027 (USD MILLION) 184

10.3.1 GERMANY 185

10.3.1.1 Germany accounts for the largest share of the European market 185

TABLE 150 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 186

TABLE 151 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 186

TABLE 152 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 187

TABLE 153 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 187

TABLE 154 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 188

10.3.2 FRANCE 188

10.3.2.1 Growing public-private collaborations for product development to drive market growth 188

TABLE 155 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 189

TABLE 156 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 189

TABLE 157 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 190

TABLE 158 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 190

TABLE 159 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 191

10.3.3 UK 191

10.3.3.1 Growing awareness of the benefits offered by POC diagnostics to support market growth in the UK 191

TABLE 160 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 192

TABLE 161 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 193

TABLE 162 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 193

TABLE 163 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 194

TABLE 164 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 194

10.3.4 ITALY 194

10.3.4.1 Rising prevalence of chronic diseases in Italy to drive the demand for point-of-care diagnostics 194

TABLE 165 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 195

TABLE 166 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 195

TABLE 167 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 196

TABLE 168 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 196

TABLE 169 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 197

10.3.5 SPAIN 197

10.3.5.1 Increasing funding for research in Spain to boost the market growth 197

TABLE 170 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 198

TABLE 171 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 198

TABLE 172 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 199

TABLE 173 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 199

TABLE 174 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 200

10.3.6 REST OF EUROPE 200

TABLE 175 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 201

TABLE 176 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 201

TABLE 177 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 202

TABLE 178 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 202

TABLE 179 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 203

10.4 ASIA PACIFIC 203

TABLE 180 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,

2020–2027 (USD MILLION) 203

TABLE 181 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 204

TABLE 182 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 204

TABLE 183 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 205

TABLE 184 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 205

TABLE 185 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 206

TABLE 186 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 206

TABLE 187 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 206

TABLE 188 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 207

TABLE 189 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,

2020–2027 (USD MILLION) 207

10.4.1 JAPAN 208

10.4.1.1 Japan to dominate the APAC POC diagnostics market during the forecast period 208

TABLE 190 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 209

TABLE 191 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 209

TABLE 192 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 210

TABLE 193 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 210

TABLE 194 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 211

10.4.2 CHINA 211

10.4.2.1 Rising investments by market players and the Chinese government to drive market growth 211

TABLE 195 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 212

TABLE 196 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 213

TABLE 197 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 213

TABLE 198 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 214

TABLE 199 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 214

10.4.3 INDIA 214

10.4.3.1 High burden of chronic diseases to support market growth 214

TABLE 200 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 216

TABLE 201 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 216

TABLE 202 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 217

TABLE 203 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 217

10.4.4 AUSTRALIA 218

10.4.4.1 Government initiatives to support the adoption of

point-of-care testing 218

TABLE 204 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 218

TABLE 205 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 219

TABLE 206 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 219

TABLE 207 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 220

TABLE 208 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 220

10.4.5 SOUTH KOREA 220

10.4.5.1 Increased funding and product development to propel market growth 220

TABLE 209 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221

TABLE 210 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 221

TABLE 211 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 222

TABLE 212 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 222

TABLE 213 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 223

10.4.6 REST OF ASIA PACIFIC 223

TABLE 214 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET,

BY PRODUCT, 2020–2027 (USD MILLION) 224

TABLE 215 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 224

TABLE 216 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 225

TABLE 217 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 225

TABLE 218 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 226

10.5 LATIN AMERICA 226

FIGURE 26 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 227

TABLE 219 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 227

TABLE 220 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 228

TABLE 221 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 228

TABLE 222 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 229

TABLE 223 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 229

TABLE 224 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 230

TABLE 225 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 230

TABLE 226 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 230

TABLE 227 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 231

TABLE 228 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 231

10.5.1 BRAZIL 232

10.5.1.1 Rising prevalence of diabetes to support market growth in Brazil 232

TABLE 229 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 232

TABLE 230 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 233

TABLE 231 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 233

TABLE 232 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 234

TABLE 233 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 234

10.5.2 MEXICO 234

10.5.2.1 Rising prevalence of diabetes and cancer to support market growth in Mexico 234

TABLE 234 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,

2020–2027 (USD MILLION) 235

TABLE 235 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 235

TABLE 236 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 236

TABLE 237 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 236

TABLE 238 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 237

10.5.3 REST OF LATIN AMERICA 237

TABLE 239 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET,

BY PRODUCT, 2020–2027 (USD MILLION) 238

TABLE 240 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 238

TABLE 241 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 239

TABLE 242 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 239

TABLE 243 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 240

10.6 MIDDLE EAST & AFRICA 240

10.6.1 RISING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH IN THE MEA 240

TABLE 244 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,

BY PRODUCT, 2020–2027 (USD MILLION) 241

TABLE 245 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 241

TABLE 246 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 242

TABLE 247 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 242

TABLE 248 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 243

TABLE 249 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE,

2020–2027 (USD MILLION) 243

TABLE 250 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,

BY PLATFORM, 2020–2027 (USD MILLION) 243

TABLE 251 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,

BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 244

TABLE 252 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,

BY END USER, 2020–2027 (USD MILLION) 244

11 COMPETITIVE LANDSCAPE 245

11.1 INTRODUCTION 245

FIGURE 27 KEY DEVELOPMENTS BY LEADING PLAYERS IN THE POINT-OF-CARE DIAGNOSTICS MARKET, JANUARY 2018–FEBRUARY 2022 246

11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 246

11.3 REVENUE SHARE ANALYSIS 247

FIGURE 28 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE

POINT-OF-CARE DIAGNOSTICS MARKET 247

11.4 MARKET SHARE ANALYSIS 248

FIGURE 29 TOTAL POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2021 248

FIGURE 30 TOTAL POINT-OF-CARE DIAGNOSTICS (WITHOUT COVID) MARKET SHARE,

BY KEY PLAYER, 2021 248

FIGURE 31 TOTAL POINT-OF-CARE DIAGNOSTICS (ONLY COVID) MARKET SHARE,

BY KEY PLAYER, 2021 249

TABLE 253 POINT-OF-CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION 249

11.5 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021) 250

11.5.1 STARS 250

11.5.2 EMERGING LEADERS 251

11.5.3 PERVASIVE PLAYERS 251

11.5.4 PARTICIPANTS 251

FIGURE 32 POINT-OF-CARE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 251

11.6 COMPETITIVE LEADERSHIP MAPPING: START-UP/ SME EVALUATION QUADRANT (2021) 252

11.6.1 PROGRESSIVE COMPANIES 252

11.6.2 RESPONSIVE COMPANIES 252

11.6.3 DYNAMIC COMPANIES 252

11.6.4 STARTING BLOCKS 252

FIGURE 33 POINT OF CARE MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS) (2021) 253

11.7 COMPETITIVE BENCHMARKING 254

TABLE 254 COMPANY FOOTPRINT ANALYSIS IN THE POINT-OF-CARE

DIAGNOSTICS MARKET 254

11.8 COMPETITIVE SCENARIO 255

11.8.1 PRODUCT LAUNCHES & APPROVALS 255

11.8.2 DEALS 262

12 COMPANY PROFILES 266

12.1 KEY PLAYERS 266

(Business Overview, Products Offered, Recent Developments, and MnM View)*

12.1.1 F. HOFFMANN-LA ROCHE LTD. 266

TABLE 255 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 266

FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021) 267

12.1.2 ABBOTT 273

TABLE 256 ABBOTT: BUSINESS OVERVIEW 273

FIGURE 35 ABBOTT: COMPANY SNAPSHOT (2021) 274

12.1.3 SIEMENS HEALTHINEERS AG 280

TABLE 257 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 280

FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 281

12.1.4 QUIDEL CORPORATION 286

TABLE 258 QUIDEL CORPORATION: BUSINESS OVERVIEW 286

FIGURE 37 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 287

12.1.5 DANAHER CORPORATION 292

TABLE 259 DANAHER CORPORATION: BUSINESS OVERVIEW 292

FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 293

12.1.6 BECTON, DICKINSON AND COMPANY 296

TABLE 260 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 296

FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 297

12.1.7 THERMO FISHER SCIENTIFIC 300

TABLE 261 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 300

FIGURE 40 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 301

12.1.8 BIOMÉRIEUX S.A. 306

TABLE 262 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW 306

FIGURE 41 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2020) 307

12.1.9 CHEMBIO DIAGNOSTICS, INC. 313

TABLE 263 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW 313

FIGURE 42 CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT (2020) 314

12.1.10 EKF DIAGNOSTICS 317

TABLE 264 EKF DIAGNOSTICS: BUSINESS OVERVIEW 317

FIGURE 43 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2020) 318

12.1.11 TRINITY BIOTECH PLC 320

TABLE 265 TRINITY BIOTECH PLC: BUSINESS OVERVIEW 320

FIGURE 44 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2020) 321

12.1.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY) 323

TABLE 266 INSTRUMENTATION LABORATORY: BUSINESS OVERVIEW 323

12.1.13 NOVA BIOMEDICAL 326

TABLE 267 NOVA BIOMEDICAL: BUSINESS OVERVIEW 326

12.1.14 PTS DIAGNOSTICS 329

TABLE 268 PTS DIAGNOSTICS: BUSINESS OVERVIEW 329

12.1.15 SEKISUI DIAGNOSTICS 331

TABLE 269 SEKISUI DIAGNOSTICS: BUSINESS OVERVIEW 331

12.1.16 HOLOGIC, INC. 333

TABLE 270 HOLOGIC, INC.: BUSINESS OVERVIEW 333

FIGURE 45 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 334

12.1.17 QIAGEN 338

TABLE 271 QIAGEN: BUSINESS OVERVIEW 338

FIGURE 46 QIAGEN: COMPANY SNAPSHOT (2021) 339

* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

12.2 OTHER PLAYERS 342

12.2.1 LIFESCAN IP HOLDINGS, LLC 342

12.2.2 ASCENSIA DIABETES CARE HOLDINGS AG 343

12.2.3 FLUXERGY 344

12.2.4 PRESCISION BIOSENSOR, INC. 345

12.2.5 ACON LABORATORIES, INC. 345

12.2.6 A. MENARINI DIAGNOSTICS S.R.L 347

12.2.7 ORASURE TECHNOLOGIES, INC. 348

12.2.8 MANKIND PHARMA 349

12.2.9 TERUMO CORPORATION 350

12.2.10 GRIFOLS, S.A. 351

12.2.11 DIASORIN S.P.A. 352

12.2.12 ACCUBIOTECH CO., LTD. 353

12.2.13 MERIDIAN BIOSCIENCE 354

12.2.14 BIOCARTIS 355

12.2.15 GENESTAT MOLECULAR DIAGNOSTICS, LLC. 356

12.2.16 ELLUME LIMITED 357

12.2.17 LUCIRA HEALTH, INC. 357

12.2.18 CUE HEALTH 358

12.2.19 BINX HEALTH, INC. 359

12.2.20 MOLBIO DIAGNOSTICS PVT. LTD. 360

12.2.21 VISBY MEDICAL, INC. 361

12.2.22 QUIKPATH PTE. LTD. 361

13 APPENDIX 362

13.1 DISCUSSION GUIDE 362

13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 367

13.3 AVAILABLE CUSTOMIZATIONS 369

13.4 RELATED REPORTS 369

13.5 AUTHOR DETAILS 370

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（診断薬）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（hepatitis）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（診断薬）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（hepatitis）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?